Choosing the Right P2Y12 Inhibitor After PCI – JAMA Cardiology
JAMA Cardiology shared a post on LinkedIn about a recent article by Giuseppe Biondi-Zoccai et al., adding:
“Editorial: A network meta-analysis of randomized clinical trials comparing clopidogrel, prasugrel, and ticagrelor in patients with Acute Coronary Syndrome (ACS) undergoing percutaneous coronary intervention (PCI) indicates that prasugrel offers the most favorable efficacy-safety profile for reducing major adverse cardiovascular events, myocardial infarction, and stent thrombosis.
Clinicians are advised that selection of a P2Y12 inhibitor should be individualized to account for patient comorbidities, bleeding risk, and concurrent therapies, with clopidogrel and ticagrelor remaining appropriate alternatives for specific scenarios.”
Title: Prasugrel – The Default P2Y12 Inhibitor After PCI for ACS?
Authors: Giuseppe Biondi-Zoccai, Salvatore Giordano, Nicola Corcione

Stay updated with Hemostasis Today.
-
Nov 18, 2026, 15:11Vansh Yaduvanshi: Why Compatible Blood Groups Do Not Always Mean Compatible Blood
-
Nov 18, 2026, 14:49Estetrol-Based Contraception in PCOS and Its Effects on Coagulation – RPTH Journal
-
Nov 18, 2026, 14:41Factor V Deficiency: Diagnostic Challenges and the Role of Combined Factor V and VIII Deficiency
-
Nov 18, 2026, 14:29Maxime Dely: When Patient Encounters Become Life Lessons
-
Nov 18, 2026, 14:23Basanta Khatiwada: Advancing Haematology Through Research and Innovation at HAEMATOCON 2026
-
Nov 18, 2026, 14:13Alvin Katumba: Sickle Cell Disease Research Recognised With a 2026 ASH Abstract Achievement Award
-
Nov 18, 2026, 13:34Vincenzo De Angelis: Strengthening Plasma Management and Quality Control in Eastern Europe
-
Nov 18, 2026, 13:34Standardizing Bleeding Outcome Assessment in Hemophilia Clinical Trials – JTH
-
Nov 18, 2026, 13:34Nicolas Gendron: The Ecological Transition in Thrombosis and Haemostasis